| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S12708 R48839 |
Bjørk (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
3.36 [2.47;4.58] C excluded (control group) |
82/2,421 82/7,950 | 164 | 2,421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12519 R48840 |
Bjørk (Valproate) (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
3.44 [2.77;4.28] excluded (control group) |
82/2,421 38,437/4,463,879 | 38,519 | 2,421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12707 R48841 |
Bjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of childhood autism (F84.0), atypical autism (F84.1), and Asperger syndrome (F84.5) (between 6.1 and 7.9 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 2.81 [2.18;3.61] C | 82/2,421 267/21,634 | 349 | 2,421 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9391 R46532 |
Coste (Valproate) (Controls exposed to Lamotrigine, sick), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
4.70 [1.90;11.40] excluded (control group) |
17/991 7/2,108 | 24 | 991 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9392 R46533 |
Coste (Valproate) (Controls unexposed, NOS), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 4.60 [2.90;7.50] | 17/991 4,280/1,710,441 | 4,297 | 991 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9430 R46536 |
Wiggs (Valproate), 2020 | Austism Spectrum Disorder (after 2 years of age) | at least 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 2.30 [1.53;3.47] | -/- -/11,298 | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9404 R46535 |
Huber-Mollema (Valproate), 2019 | Diagnosis of autism spectrum disorder | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.74 [0.57;13.12] C | 3/26 4/88 | 7 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9981 R46538 |
Bjørk (Valproate) (Controls exposed to Lamotrigine, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
0.61 [0.16;2.31] C excluded (control group) |
3/27 13/76 | 16 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9982 R46539 |
Bjørk (Valproate) (Controls unexposed, disease free), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, disease free excluded | Adjustment: No |
1.24 [0.37;4.12] C excluded (control group) |
3/27 6,907/75,497 | 6,910 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9983 R46540 |
Bjørk (Valproate) (Controls unexposed, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 1.13 [0.32;4.02] C | 3/27 27/272 | 30 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9431 R46537 |
Wood (Valproate), 2015 | Score >30 (CARS) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.04 [0.04;28.06] C | 1/26 0/9 | 1 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9377 R46527 |
Bromley (Valproate) (Controls exposed to Lamotrigine, sick), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.52 [0.27;23.69] C excluded (control group) |
4/50 1/30 | 5 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9380 R46528 |
Bromley (Valproate) (Controls unexposed, disease free), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
4.57 [1.10;18.93] C excluded (control group) |
4/50 4/214 | 8 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9383 R46529 |
Bromley (Valproate) (Controls unexposed, sick), 2013 | Autistic Spectrum Disorders (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 5.04 [0.26;97.51] C | 4/50 0/26 | 4 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9278 R46526 |
Adab (Valproate), 2004 | Asperger’s syndrome | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 4.90 [0.20;122.25] C | 1/63 0/101 | 1 | 63 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 8 studies | 2.86 [2.28;3.58] | 4,689 | 3,604 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Valproate) (Controls unexposed, sick) (Mixed indications; 2: Valproate) (Controls unexposed, NOS; 3: Valproate; 4: Valproate; 5: Valproate) (Controls unexposed, sick; 6: Valproate; 7: Valproate) (Controls unexposed, sick; 8: Valproate;
Asymetry test p-value = 0.8026 (by Egger's regression)
slope=1.0790 (0.1604); intercept=-0.1526 (0.5838); t=0.2613; p=0.8026
excluded 9377, 9380, 9981, 9982, 9391, 12708, 12519